clinical trial · NCT00275444
3 TPV/RTV Doses in Multiple ARV Experienced Patients - Tipranavir Dose Defining Study
Boehringer Ingelheim·phase2·completed·n = 216
HIV InfectionsTipranavir
brief summary
A dose defining study of the protease inhibitor tipranavir (TPV), boosted with low dose ritonavir (RTV). Three dose combinations of TPV/RTV are administered to multiple antiretroviral experienced patients and the dose that achieves the best efficacy and safety as determined by evaluation of 2, 8, and 24-week virologic response and adverse event and laboratory profile measures would be selected for further clinical study.
started
Mar 29, 2002
primary completion
Jan 20, 2003
completion
—
last updated
Dec 1, 2023
official title
Double-blind, Randomized, Dose Optimization Trial of Three Doses of Tipranavir Boosted With Low Dose Ritonavir (TPV/RTV) in Multiple Antiretroviral Drug-experienced Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol